<?xml version='1.0' encoding='utf-8'?>
<document id="31382371"><sentence text="Pharmacokinetic Evaluation of Metabolic Drug Interactions between Repaglinide and Celecoxib by a Bioanalytical HPLC Method for Their Simultaneous Determination with Fluorescence Detection."><entity charOffset="66-77" id="DDI-PubMed.31382371.s1.e0" text="Repaglinide" /><entity charOffset="82-91" id="DDI-PubMed.31382371.s1.e1" text="Celecoxib" /><pair ddi="false" e1="DDI-PubMed.31382371.s1.e0" e2="DDI-PubMed.31382371.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31382371.s1.e0" e2="DDI-PubMed.31382371.s1.e1" /></sentence><sentence text="Since diabetes mellitus and osteoarthritis are highly prevalent diseases, combinations of antidiabetic agents like repaglinide (REP) and non-steroidal anti-inflammatory drugs (NSAID) like celecoxib (CEL) could be commonly used in clinical practice"><entity charOffset="115-126" id="DDI-PubMed.31382371.s2.e0" text="repaglinide" /><entity charOffset="128-131" id="DDI-PubMed.31382371.s2.e1" text="REP" /><entity charOffset="188-197" id="DDI-PubMed.31382371.s2.e2" text="celecoxib" /><entity charOffset="199-202" id="DDI-PubMed.31382371.s2.e3" text="CEL" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e0" e2="DDI-PubMed.31382371.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e0" e2="DDI-PubMed.31382371.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e0" e2="DDI-PubMed.31382371.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e0" e2="DDI-PubMed.31382371.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e1" e2="DDI-PubMed.31382371.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e1" e2="DDI-PubMed.31382371.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e1" e2="DDI-PubMed.31382371.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e2" e2="DDI-PubMed.31382371.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31382371.s2.e2" e2="DDI-PubMed.31382371.s2.e3" /></sentence><sentence text=" In this study, a simple and sensitive bioanalytical HPLC method combined with fluorescence detector (HPLC-FL) was developed and fully validated for simultaneous quantification of REP and CEL"><entity charOffset="180-182" id="DDI-PubMed.31382371.s3.e0" text="REP" /><entity charOffset="188-190" id="DDI-PubMed.31382371.s3.e1" text="CEL" /><pair ddi="false" e1="DDI-PubMed.31382371.s3.e0" e2="DDI-PubMed.31382371.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31382371.s3.e0" e2="DDI-PubMed.31382371.s3.e1" /></sentence><sentence text=" A simple protein precipitation procedure and reversed C18 column with an isocratic mobile phase (mixture of ACN and pH 6" /><sentence text="0 phosphate buffer) were employed for sample preparation and chromatographic separation" /><sentence text=" The fluorescence detector was set at a single excitation/emission wavelength pair of 240 nm/380 nm" /><sentence text=" The linearity (10-2000 ng/mL), accuracy, precision, extraction recovery, matrix effect, and stability for this method were validated as per the current FDA guidance" /><sentence text=" The bioanalytical method was applied to study pharmacokinetic interactions between REP and CEL in vivo, successfully showing that concurrent administration with oral REP significantly altered the pharmacokinetics of oral CEL"><entity charOffset="84-86" id="DDI-PubMed.31382371.s8.e0" text="REP" /><entity charOffset="167-169" id="DDI-PubMed.31382371.s8.e1" text="REP" /><entity charOffset="92-94" id="DDI-PubMed.31382371.s8.e2" text="CEL" /><entity charOffset="222-224" id="DDI-PubMed.31382371.s8.e3" text="CEL" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e0" e2="DDI-PubMed.31382371.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e0" e2="DDI-PubMed.31382371.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e0" e2="DDI-PubMed.31382371.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e0" e2="DDI-PubMed.31382371.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e2" e2="DDI-PubMed.31382371.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e2" e2="DDI-PubMed.31382371.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e2" e2="DDI-PubMed.31382371.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e1" e2="DDI-PubMed.31382371.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s8.e1" e2="DDI-PubMed.31382371.s8.e3" /></sentence><sentence text=" Furthermore, an in vitro metabolism and protein binding study using human materials highlighted the possibility of metabolism-based interactions between CEL and REP in clinical settings"><entity charOffset="162-164" id="DDI-PubMed.31382371.s9.e0" text="REP" /><entity charOffset="154-156" id="DDI-PubMed.31382371.s9.e1" text="CEL" /><pair ddi="false" e1="DDI-PubMed.31382371.s9.e1" e2="DDI-PubMed.31382371.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31382371.s9.e1" e2="DDI-PubMed.31382371.s9.e0" /></sentence><sentence text="" /></document>